Guillaume Laurent Lessene

This inventor holds 11 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 9 EPO patents. Top assignees: Walter and Eliza Hall Institute of Medical Research, Genentech, Inc., Abbvie Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guillaume Laurent Lessene. Retrieved from https://idiyas.com/inventor/guillaume-laurent-lessene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 9)

% Patents Active = 81.8

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 151(Granted Patents)

Location History:

Coburg, AU (2011 - 2015)
Parkville, AU (2015)
Bundoora, AU (2015 - 2020)

Company Filing History:

8 out of 84

Walter and Eliza Hall Institute of Medical Research

Abbott Laboratories Corporation

patents

5. 1 out of 1

Anaxis Pharma Pty Ltd

patent

6. 1 out of 53

Les Laboratories Servier

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583836 - Sulphonamide compounds (2026-03-24),

2. 10765680 - Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof (2020-09-08),

3. 9221799 - Anti-cancer agents (2015-12-29),

4. 9067928 - Compounds and methods of use (2015-06-30),

5. 8962830 - Protein kinase inhibitors and methods of treatment (2015-02-24),

6. 8952157 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2015-02-10),

7. 8518970 - Compounds and methods of use (2013-08-27),

8. 8232273 - Heterocyclic compounds and methods of use (2012-07-31),

9. 8168645 - Arylsulfonamide compounds (2012-05-01),

10. 8114893 - Compounds and methods of use (2012-02-14),

11. 7956216 - Alpha-helical mimetics (2011-06-07),

Title: **The Innovative Contributions of Guillaume Laurent Lessene in Cancer Research**

Introduction

Guillaume Laurent Lessene is a notable inventor based in Parkville, Australia, recognized for his significant contributions to the field of cancer research. With a remarkable portfolio of 10 patents, Lessene's work primarily focuses on innovative pharmaceutical compounds and treatments aimed at combating cancer.

Latest Patents

Among Lessene's latest patents is the groundbreaking invention of a combination of a MCL-1 inhibitor and a taxane compound. This innovative approach presents a novel method for treating cancer, providing compositions and uses that can improve therapeutic outcomes. Additionally, he has developed another vital patent related to anti-cancer agents, which revolves around a specific compound of Formula (I) and its pharmaceutical acceptable derivatives, salts, or prodrugs. This invention outlines a method for treating cancer by administering effective amounts of this compound, showcasing its potential in preparing medicaments for cancer treatment.

Career Highlights

Lessene's illustrious career includes significant positions at esteemed organizations such as the Walter and Eliza Hall Institute of Medical Research and Genentech, Inc. His work within these institutions has not only advanced cancer research but also paved the way for innovative drug development strategies.

Collaborations

Throughout his career, Lessene has collaborated with prominent figures in the scientific community, including Jonathan Bayldon Baell and Peter Colman. These collaborations have further strengthened his research efforts and contributed to his success in developing innovative cancer treatment solutions.

Conclusion

Guillaume Laurent Lessene stands out as a pivotal figure in the realm of cancer research, with his patents exemplifying the intersection of innovation and life-saving medical advances. His contributions continue to inspire future research endeavors in the fight against cancer, showcasing the importance of inventive thought in transforming medical practices.

Profile summary based on public USPTO records.